US Patent

US11559530 — Oral testosterone undecanoate therapy

Method of Use · Assigned to Lipocine Inc · Expires 2037-11-28 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for testosterone replacement therapy using a fixed dose dosing regimen.

USPTO Abstract

The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels.

Drugs covered by this patent

Aveed (TESTOSTERONE UNDECANOATE) · Marius

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1500`	—	Aveed

Patent Metadata

Patent number: US11559530
Jurisdiction: US
Classification: Method of Use
Expires: 2037-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Lipocine Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.